LONG-TERM EFFECTS OF A SOMATOSTATIN ANALOG ON RENAL HEMODYNAMICS AND HYPERTROPHY IN DIABETIC RATS

被引:9
作者
MUNTZEL, M
HANNEDOUCHE, T
NIESOR, R
NOEL, LH
SOUBERBIELLE, JC
LACOUR, B
DRUEKE, T
机构
[1] HOP NECKER ENFANTS MALAD,DEPT NEPHROL,INSERM,UNIT 90,F-75730 PARIS 15,FRANCE
[2] HOP NECKER ENFANTS MALAD,DEPT PHYSIOL,INSERM,UNIT 90,F-75730 PARIS 15,FRANCE
关键词
DIABETES; HYPERTROPHY; OCTREOTIDE; PROTEINURIA; RENAL HEMODYNAMICS; SOMATOSTATIN; STREPTOZOTOCIN;
D O I
10.1042/cs0830575
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
1. To determine whether treatment with octreotide, a somatostatin analogue, may diminish or prevent long-term diabetic renal hypertrophy and nephropathy, uninephrectomized streptozotocin-diabetic rats maintained under moderate glycaemic control (approximately 300 mg/dl) were treated with either placebo (n = 10 rat/group) or octreotide for 14 weeks. Uninephrectomized non-diabetic rats given either placebo or octreotide served as controls. 2. Average body weight was diminished and kidney weight, daily urinary protein excretion, glomerular filtration rate and renal plasma flow were elevated in both diabetic groups relative to controls. 3. Administration of octreotide reduced average body weight and packed cell volume in non-diabetic and diabetic rats compared with their respective controls, but did not affect glomerular hyperfiltration or the increase in urinary protein excretion. 4. Histological examination at 14 weeks disclosed unequivocal glomerular hypertrophy and mild glomerular and tubulointerstitial lesions consistent with early diabetic renal alterations in all diabetic rats, but there was no independent effect of octreotide treatment. 5. Thus, long-term treatment with octreotide did not afford protection against the development of renal hypertrophy-hyperfiltration and the evolution of early diabetic nephropathy in rats.
引用
收藏
页码:575 / 581
页数:7
相关论文
共 31 条
[1]  
ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
[2]   PATHOGENESIS OF DIABETIC GLOMERULOPATHY - HEMODYNAMIC CONSIDERATIONS [J].
ANDERSON, S ;
BRENNER, BM .
DIABETES-METABOLISM REVIEWS, 1988, 4 (02) :163-177
[3]  
BAYER W, 1982, LIFE SCI, V31, P1133
[4]   RADIOIMMUNOASSAY FOR INSULIN-LIKE GROWTH FACTOR-I - SOLUTIONS TO SOME POTENTIAL PROBLEMS AND PITFALLS [J].
BREIER, BH ;
GALLAHER, BW ;
GLUCKMAN, PD .
JOURNAL OF ENDOCRINOLOGY, 1991, 128 (03) :347-357
[5]  
DOI T, 1988, AM J PATHOL, V131, P398
[6]   GLOMERULOSCLEROSIS - INSIGHTS INTO PATHOGENESIS AND TREATMENT [J].
ELNAHAS, AM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1989, 4 (10) :843-853
[7]   COMPENSATORY RENAL GROWTH - ROLE OF GROWTH-HORMONE AND INSULIN-LIKE GROWTH FACTOR-I [J].
ELNAHAS, AM ;
LECARPENTIER, JE ;
BASSETT, AH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1990, 5 (02) :123-129
[8]   COORDINATE DECREASE OF TISSUE INSULINLIKE GROWTH FACTOR-I POSTTRANSCRIPTIONAL ALTERNATIVE MESSENGER-RNA TRANSCRIPTS IN DIABETES-MELLITUS [J].
FAGIN, JA ;
ROBERTS, CT ;
LEROITH, D ;
BROWN, AT .
DIABETES, 1989, 38 (04) :428-434
[9]   KIDNEY IGF-I MESSENGER-RNA IN INITIAL RENAL HYPERTROPHY IN EXPERIMENTAL DIABETES IN RATS [J].
FLYVBJERG, A ;
BORNFELDT, KE ;
MARSHALL, SM ;
ARNQVIST, HJ ;
ORSKOV, H .
DIABETOLOGIA, 1990, 33 (06) :334-338
[10]   SOMATOSTATIN ANALOG ADMINISTRATION PREVENTS INCREASE IN KIDNEY SOMATOMEDIN-C AND INITIAL RENAL GROWTH IN DIABETIC AND UNINEPHRECTOMIZED RATS [J].
FLYVBJERG, A ;
FRYSTYK, J ;
THORLACIUSUSSING, O ;
ORSKOV, H .
DIABETOLOGIA, 1989, 32 (04) :261-265